Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 25 were puts, with a value of $2,613,444, and 4 were calls, valued at $204,739.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $125.0 to $220.0 for Insmed during the past quarter.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Insmed’s options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Insmed’s substantial trades, within a strike price spectrum from $125.0 to $220.0 over the preceding 30 days.
Insmed 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INSM | PUT | SWEEP | NEUTRAL | 10/17/25 | $6.4 | $5.8 | $5.8 | $140.00 | $483.9K | 144 | 1.3K |
| INSM | PUT | SWEEP | BEARISH | 10/17/25 | $5.0 | $2.65 | $4.8 | $135.00 | $320.4K | 679 | 1.0K |
| INSM | PUT | SWEEP | BEARISH | 10/17/25 | $5.9 | $4.9 | $4.9 | $135.00 | $252.3K | 679 | 2.0K |
| INSM | PUT | SWEEP | BEARISH | 10/17/25 | $5.6 | $5.5 | $5.6 | $140.00 | $192.4K | 144 | 522 |
| INSM | PUT | SWEEP | BEARISH | 10/17/25 | $4.1 | $2.5 | $4.1 | $135.00 | $133.2K | 679 | 355 |
About Insmed
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company’s first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
After a thorough review of the options trading surrounding Insmed, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Insmed
- Trading volume stands at 1,127,420, with INSM’s price down by -3.5%, positioned at $136.06.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 35 days.
What Analysts Are Saying About Insmed
In the last month, 2 experts released ratings on this stock with an average target price of $171.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge’s Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* An analyst from Guggenheim persists with their Buy rating on Insmed, maintaining a target price of $172.
* An analyst from Wells Fargo has decided to maintain their Overweight rating on Insmed, which currently sits at a price target of $171.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Insmed with Benzinga Pro for real-time alerts.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.